Select Page
Peter F. Orio III, DO, MS

Peter F. Orio III, DO, MS

Dana-Farber Brigham Cancer Centers / Harvard Medical School

Boston, Massachusetts

Peter F. Orio III, DO, MS, is Vice Chair of Network Operations for the Dana Farber Brigham Cancer Centers in Boston, Massachusetts. He also serves as the Director of Prostate Brachytherapy for the Dana Farber Brigham Cancer Centers and is an Associate Professor at Harvard Medical School. Dr. Orio earned his Bachelor of Arts in Biology/Psychology from the College of the Holy Cross, his Master’s of Science in Public Health from the University of Massachusetts at Amherst and his Doctor of Osteopathic Medicine degree from the University of New England College of Osteopathic Medicine. He completed his residency in radiation oncology at the University of Washington Medical Center. Dr. Orio served in the US Army as Assistant Chief of Radiation Oncology at Brooke Army Medical Center, where he rose to the rank of Lieutenant Colonel. Dr. Orio is active in the American Brachytherapy Society (ABS) and the American Society for Radiation Oncology (ASTRO), focusing his efforts on the advancement of brachytherapy for prostate cancer and the socioeconomics of medicine.

Disclosures:

Talks by Peter F. Orio III, DO, MS

Brian Moran Distinguished Lecture: Mobilizing Moran’s Army from Seed to Shining Seed

Brian Moran Distinguished Lecture: Mobilizing Moran’s Army from Seed to Shining Seed

Posted by | Sep 2024

Over the course of his career to date, Dr. Moran’s emphasis on quality of life issues and long-term outcomes for prostate cancer patients is evident, and his contributions to the fight against prostate cancer, such as performing over 30,000 prostate seed implant procedures and founding the Chicago Prostate Cancer Center, are innumerable.

Dr. Moran is a member of multiple specialty societies, including the American Society of Therapeutic Radiology and Oncology, the American College of Radiology, and the American Brachytherapy Society. To learn more about Dr. Moran, please visit his Author Page on Grand Rounds in Urology.

The inaugural lecture was given at IPCU 34 by Peter F. Orio III, DO, MS.

Read More
New Spacer Technology for Prostate Cancer Radiation Therapy

New Spacer Technology for Prostate Cancer Radiation Therapy

Posted by | Oct 2023

Peter F. Orio III, DO, MS, discusses the critical role of rectal spacing in reducing the toxicity associated with radiation therapies in the treatment of prostate cancer. While not yet FDA approved, Dr. Orio reviews several pivotal trials on SpaceOAR and Barrigel which support the use of rectal spacing technology in prostate cancer treatment.

Dr. Orio underscores the role of rectal spacing technology in a patient-centric approach to cancer care. Throughout his presentation, Dr. Orio focuses on the mechanisms behind rectal spacing technology which preserve patient quality of life more effectively than traditional approaches when done correctly.

Dr. Orio then reviews the weaknesses and dangers of rectal spacer technology and analyzes reports in the FDA MAUDE database for SpaceOAR Classic, SpaceOAR Vue, and Barrigel. He cautions physicians and surgeons to know their own skill-level and to always choose the safety of the patient.

Read More
Treatment of Localized Disease

Treatment of Localized Disease

Posted by | Sep 2023

Peter F. Orio III, DO, MS, discusses the treatment of localized prostate cancer, with emphasis on maximizing the value for the patient. Dr. Orio explains Michael Porter’s equation for determining patient value: patient-relevant outcomes, divided by the cost to achieve the outcomes.

Dr. Orio then reviews the benefits and limitations of common treatments for prostate cancer, including:

External Beam Radiation Therapy with and without Androgen Deprivation Therapy
Brachytherapy
Radical Prostatectomy with and without Pelvic Lymph Node Dissection
Focal Therapies

Dr. Orio concludes by emphasizing that the goal of treatment is to cure the patient and avoid reducing QoL as much as possible. As long as the physician keeps that goal top of mind, the journey to remission will be different for every patient

Read More
Identification of Localized Disease

Identification of Localized Disease

Posted by | Jul 2023

Peter F. Orio III, DO, MS, discusses the process of identifying localized prostate cancer. Dr. Orio emphasizes that prostate cancer is a spectrum of disease, rather than a binary, as prostate cancer is not necessarily confined to the prostate organ alone, and that the ultimate goal of treatment is reduction of harm to the patient’s future self.

Dr. Orio reviews the current screening, imaging, and testing steps to identifying localized prostate cancer, including the best candidates for screening. He notes that mandatory DREs discourages patients from coming in to the urologist, and suggests that screening should eliminate them.

Dr. Orio offers the more sensitive and less invasive PSA tests in combination with MRIs as an alternative first step in screening. He concludes by offering PSA – MRI – Fusion Biopsy – Germline Testing – FHX – FNX Imaging as the new path for screening and identifying localized prostate cancer.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -